Lifevantage (NASDAQ:LFVN) Share Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Technical breach: LifeVantage shares fell below their 200‑day moving average of $6.04, trading as low as $4.71 and last at $4.96 on volume of 923,481 shares, signaling increased downside pressure.
• Weak quarter but guided for FY2026: The company missed Q results (EPS $0.15 vs. $0.22 expected; revenue $48.93M vs. $54.4M) but set FY2026 EPS guidance of $0.60–0.80; analysts’ consensus target is $5.00 with an average rating of "Moderate Buy."
• Income and insider support: LifeVantage pays a $0.18 annualized dividend (3.6% yield) and insiders have been buying shares—Director Judd Dayton added 10,500 shares—while insiders own roughly 21.95% of the company.

Lifevantage Corporation (NASDAQ:LFVN - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.04 and traded as low as $4.71. Lifevantage shares last traded at $4.96, with a volume of 923,481 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on LFVN shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Lifevantage in a report on Friday, March 27th. Lake Street Capital reissued a "buy" rating on shares of Lifevantage in a research note on Thursday, February 5th. Finally, Loop Capital set a $5.00 target price on Lifevantage in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $5.00.

Lifevantage Stock Up 1.2%

The stock's 50-day moving average price is $4.64 and its 200-day moving average price is $6.04. The company has a market capitalization of $63.54 million, a price-to-earnings ratio of 8.27 and a beta of 0.36.

Lifevantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.07). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The company had revenue of $48.93 million during the quarter, compared to analyst estimates of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS. On average, equities research analysts anticipate that Lifevantage Corporation will post 0.65 EPS for the current year.

Lifevantage Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 16th. Stockholders of record on Monday, March 2nd were paid a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend was Monday, March 2nd. Lifevantage's dividend payout ratio (DPR) is 30.00%.

Insider Activity at Lifevantage

In other news, Director Judd Dayton bought 10,500 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $4.53 per share, for a total transaction of $47,565.00. Following the completion of the transaction, the director directly owned 80,359 shares in the company, valued at $364,026.27. The trade was a 15.03% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders acquired 38,207 shares of company stock valued at $178,585. 21.95% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lifevantage

Several hedge funds have recently added to or reduced their stakes in LFVN. JPMorgan Chase & Co. increased its position in Lifevantage by 870.2% in the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company's stock worth $66,000 after purchasing an additional 4,499 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage during the 2nd quarter valued at about $76,000. BNP Paribas Financial Markets boosted its stake in shares of Lifevantage by 2,555.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company's stock valued at $80,000 after purchasing an additional 5,904 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Lifevantage in the 1st quarter valued at about $97,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Lifevantage during the 2nd quarter worth approximately $102,000. Institutional investors own 35.32% of the company's stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.